Evaluating non-hormonal therapy in a phase II trial of SM-88 for rising PSA prostate cancer.

Benjamin Adam Gartrell; Giuseppe Del Priore; Avi S. Retter; Wen-Tien Chen; Gerald H. Sokol; Alexander G Vandell; Mack Roach

doi:10.1200/JCO.2019.37.7_SUPPL.83

Evaluating non-hormonal therapy in a phase II trial of SM-88 for rising PSA prostate cancer.

Benjamin Adam Gartrell
, Giuseppe Del Priore
, Avi S. Retter
, Wen-Tien Chen
, Gerald H. Sokol
, Alexander G Vandell
, Mack Roach

Albert Einstein College of Medicine
Morehouse School of Medicine
Eastchester Center for Cancer Care, Bergenfield, NJ;
Stony Brook University
Florida Cancer Institute New Hope, Hudson, FL;
Tyme Inc, New York, NY;
University of California, San Francisco

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Journal of Clinical Oncology
Volume	37
DOIs	https://doi.org/10.1200/JCO.2019.37.7_SUPPL.83
State	Published - Feb 26 2019
Externally published	Yes

Disciplines

Medicine and Health Sciences
Oncology
Internal Medicine

Access to Document

10.1200/JCO.2019.37.7_SUPPL.83License: Unspecified

Cite this

@article{e52f6c1dd72a4d9d9cc4ac6c57840e6f,

title = "Evaluating non-hormonal therapy in a phase II trial of SM-88 for rising PSA prostate cancer.",

author = "Gartrell, \{Benjamin Adam\} and \{Del Priore\}, Giuseppe and Retter, \{Avi S.\} and Wen-Tien Chen and Sokol, \{Gerald H.\} and Vandell, \{Alexander G\} and Mack Roach",

note = "83 Background: Absolute PSA change is an imperfect surrogate of clinical benefit; CTCs and PSA doubling time (DT) may also be used as a surrogate of progression (PD). Hormone therapy (HT) often leads to a rapid decline in PSA, however non-HT may be effective without causing a decline in absolute PSA or testosterone (T).",

year = "2019",

month = feb,

day = "26",

doi = "10.1200/JCO.2019.37.7\_SUPPL.83",

language = "American English",

volume = "37",

journal = "Journal of Clinical Oncology",

}

TY - JOUR

T1 - Evaluating non-hormonal therapy in a phase II trial of SM-88 for rising PSA prostate cancer.

AU - Gartrell, Benjamin Adam

AU - Del Priore, Giuseppe

AU - Retter, Avi S.

AU - Chen, Wen-Tien

AU - Sokol, Gerald H.

AU - Vandell, Alexander G

AU - Roach, Mack

N1 - 83 Background: Absolute PSA change is an imperfect surrogate of clinical benefit; CTCs and PSA doubling time (DT) may also be used as a surrogate of progression (PD). Hormone therapy (HT) often leads to a rapid decline in PSA, however non-HT may be effective without causing a decline in absolute PSA or testosterone (T).

PY - 2019/2/26

Y1 - 2019/2/26

UR - https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.7_suppl.83

U2 - 10.1200/JCO.2019.37.7_SUPPL.83

DO - 10.1200/JCO.2019.37.7_SUPPL.83

M3 - Article

VL - 37

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

ER -

Evaluating non-hormonal therapy in a phase II trial of SM-88 for rising PSA prostate cancer.

Disciplines

Access to Document

Other files and links

Cite this